Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier
Authors:
Open Access
- 19 November 2021
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 29, 100822
Abstract
No abstract availableKeywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (451-03-68/2020-14/ 200042)
This publication has 48 references indexed in Scilit:
- Molecular Genetics and Genotype-Based Estimation of BH4-Responsiveness in Serbian PKU Patients: Spotlight on Phenotypic Implications of p.L48S2012
- Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardationNature Genetics, 2010
- Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA NanoarraysScience, 2010
- Pathogenesis of cognitive dysfunction in phenylketonuria: Review of hypotheses☆Molecular Genetics and Metabolism, 2010
- Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted dietJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause?Journal of Inherited Metabolic Disease, 2009
- Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disordersNature Genetics, 2006
- Large neutral amino acids in the treatment of phenylketonuria (PKU)Journal of Inherited Metabolic Disease, 2006
- LAT1 gene variants—potential factors influencing the clinical course of phenylketonuriaJournal of Inherited Metabolic Disease, 2006
- β-Phenylpyruvate induces long-term neurobehavioral damage and brain necrosis in neonatal miceBehavioural Brain Research, 2003